Evidence map›Paper›PMID 11375250›Full record

ArticleBritish journal of pharmacology2001

Synergistic protective effect of caspase inhibitors and bFGF against brain injury induced by transient focal ischaemia.

J Ma, J Qiu, L Hirt, T Dalkara, M A Moskowitz

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2015
    Article
  9. Article
  10. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2009
    Article
  11. Review
  12. Review
  13. Clinical trials for cytoprotection in stroke.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2004
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J MaStroke and Neurovascular Regulation Laboratory, Neurology and Neurosurgery Services, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
J Qiu
L Hirt
T Dalkara
M A Moskowitz
Hacettepe University · TR

Funding

TRIGEMINOVASCULAR CONTROL OF CEREBRAL BLOOD VESSELSP50NS010828 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI LO, ENG H. · 1985 to 2007
$10.8M
Role of protein kinase Akt in cerebral ischemiaP01NS010828 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI MOSKOWITZ, MICHAEL A. · 1989 to 2008
$1.4M
INACTIVATION OF DELAYED RECTIFIER POTASSIUM CHANNELSF32NS010828 · NINDS · UNIVERSITY OF FLORIDA · PI FRAZIER, CHARLES J · 1999 to 2001
$80k
NINDS NIH HHS F32 NS010828NINDS NIH HHS NS10828NINDS NIH HHS NS374141-02NINDS NIH HHS P01 NS010828NINDS NIH HHS P50 NS010828
6 · The paper itself

Abstract

We tested the hypothesis that combined use of trophic factors and caspase inhibitors increases brain resistance to ischaemia in mice. Intracerebroventricular administration of bFGF (>10 ng) 30 min after MCA occlusion decreased infarct size and neurological deficit in a dose-dependent manner following 2 h ischemia and reperfusion (20 h). Combined administration of the subthreshold doses of bFGF (3 ng) and caspase inhibitors (z-VAD.FMK, 27 ng or z-DEVD.FMK, 80 mg) reduced infarct volume by 60%, and reduced neurological deficit. Treatment with a subthreshold dose of bFGF (3 ng) extended the therapeutic window for z-DEVD.FMK (480 ng) from 1 to 3 h after reperfusion. Caspase-3 activity in the ischaemic brain was increased 30 min and 2 h after reperfusion but, was significantly reduced in bFGF-treated animals by 29 and 16%, respectively. Caspase-3 activity was not reduced by a direct bFGF effect because addition of bFGF (10 nM - 2 microM) did not decrease recombinant caspase-3 activity, in vitro. Our data show that combining caspase inhibitors and bFGF lengthens the treatment window for the second treatment, plus lowers the dosage requirements for neuroprotection. These findings are important because low doses of caspase inhibitors or bFGF reduce the possibility of side effects plus extend the short treatment window for ischaemic stroke.

Indexed as

Caspase InhibitorsAmino Acid Chloromethyl KetonesAnimalsBrain IschemiaCaspase 3CaspasesCysteine Proteinase InhibitorsDose-Response Relationship, DrugDrug SynergismDrug Therapy, CombinationFibroblast Growth Factor 2MaleMiceNeuroprotective AgentsOligopeptidesAmino Acid Chloromethyl Ketonesbenzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketonebenzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneCasp3 protein, mouseCaspase 3Caspase InhibitorsCaspasesCysteine Proteinase InhibitorsFibroblast Growth Factor 2Neuroprotective AgentsOligopeptides

Identifiers

PMID11375250
PMCPMC1572791
OpenAlexW2083954838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.